Feb 16, 2021

RSIP Vision launches AI tool for coronary assessment

AI
coronary disease
computer vision
deep learning
Leila Hawkins
2 min
   RSIP Vision launches AI tool for coronary assessment
The new module uses state-of-the-art deep learning algorithms and computer vision methods to create a 3D model of the coronary arteries...

The new module uses state-of-the-art deep learning algorithms and computer vision methods to create a 3D model of the coronary arteries

Medical imaging company RSIP Vision are launching a tool powered by AI and computer vision that will help with coronary artery analysis and intervention planning. 

The fully automated solution provides an accurate 3D model of coronary artery anatomy, giving precise measurements of the artery length and diameter at any point. This aims to help clinicians perform image-based assessments of coronary artery function and diagnose conditions like artery narrowing, known as stenosis. 

It will also help physicians with advanced procedure planning, including stent selection and stent positioning. Additional modules can show artery modification as a result of stent placement, or place a virtual stent in the desired position within the coronary artery. These replace invasive cardiac measurements. 

“The cardiac CT-scan contains vast amounts of data surrounding the coronary arteries, and our mission is to extract it” Ron Soferman, founder & CEO at RSIP Vision said. “Its wide availability and excellent resolution make it a preferred imaging modality for cardiology purposes. 

“We are pleased to introduce our new module that will aid in the detection of coronary artery stenosis and be useful in coronary intervention (PCI) planning. We believe strongly this will reduce the need for additional interventions, while decreasing the chance of adverse events due to incorrect stent selection.”

Dr. David Yakobi, Board Certified Cardiac Surgeon, explained that proper pre-procedural planning is essential for any invasive cardiac intervention. “Any automated technology that eliminates human error and bias contributors has the potential to augment procedural success, increase stent patency rate in the long-run and avoid unnecessary consecutive interventions. 

“This module will also allow us to integrate its analytical findings and classify the severity of patient’s combined coronary stenoses, so the interventional cardiologist can predict the outcome of the procedure to guide the choice between coronary intervention and CABG (Coronary Artery Bypass Surgery) and predict long-term survival.”

RSIP Vision has 25 years’ experience in medical imaging. Going forward, they plan to extend the functionalities of this new tool, including calcification detection, support for pre-existing stents, and 3D reconstruction from 2-dimensional X-rays. 

Share article

Jun 18, 2021

Skin Analytics wins NHSX award for AI skin cancer tool 

AI
NHS
skincancer
Cancer
2 min
Skin Analytics uses AI to detect skin cancer and will be deployed across the NHS to ease patient backlogs

An artificial intelligence-driven tool that identifies skin cancers has received an award from NHSX, the NHS England and Department of Health and Social Care's initiative to bring technology into the UK's national health system. 

NHSX has granted the Artificial Intelligence in Health and Care Award to DERM, an AI solution that can identify 11 types of skin lesion. 

Developed by Skin Analytics, DERM analyses images of skin lesions using algorithms. Within primary care, Skin Analytics will be used as an additional tool to help doctors with their decision making. 

In secondary care, it enables AI telehealth hubs to support dermatologists with triage, directing patients to the right next step. This will help speed up diagnosis, and patients with benign skin lesions can be identified earlier, redirecting them away from dermatology departments that are at full capacity due to the COVID-19 backlog. 

Cancer Research has called the impact of the pandemic on cancer services "devastating", with a 42% drop in the number of people starting cancer treatment after screening. 

DERM is already in use at University Hospitals Birmingham and Mid and South Essex Health & Care Partnership, where it has led to a significant reduction in unnecessary referrals to hospital.

Now NHSX have granted it the Phase 4 AI in Health and Care Award, making DERM available to clinicians across the country. Overall this award makes £140 million available over four years to accelerate the use of artificial intelligence technologies which meet the aims of the NHS Long Term Plan.

Dr Lucy Thomas, Consultant Dermatologist at Chelsea & Westminster Hospital, said: “Skin Analytics’ receipt of this award is great news for the NHS and dermatology departments. It will allow us to gather real-world data to demonstrate the benefits of AI on patient pathways and workforce challenges. 

"Like many services, dermatology has severe backlogs due to the COVID-19 pandemic. This award couldn't have come at a better time to aid recovery and give us more time with the patients most in need of our help.”

Share article